Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

Melanoma

A Phase 2 study to investigate the efficacy and safety of lerapolturev alone or in
combination with a programmed death receptor-1 (anti-PD-1) inhibitor.
Melanoma
II
Johnson, Douglas
NCT04577807
VICCMEL20109

To learn more about any of our clinical
trials, call 615-936-8422.